Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

The Impact of Bile Salt Hydrolase on Intestinal T Cells in Colitis

Award Number: F31DK145221
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 03/26/2026
PERIOD OF PERFORMANCE END DATE: 03/25/2029

Group Awards By:

View Award Description

The Impact of Bile Salt Hydrolase on Intestinal T Cells in Colitis - PROJECT SUMMARY/ABSTRACT Inflammatory bowel disease (IBD) affects up to 3.1 million adults in the U.S. Bile acids are recognized as key signaling molecules in microbe-immune communication and may therefore be new therapeutic targets for IBD. Microbes deconjugate bile acids with bile salt hydrolases (BSHs), which can produce a variety of bacterial bile acid amidates (BBAAs). However, whether the microbiome affects the immune system through BBAAs remains a gap in knowledge. To investigate this, there is a critical need for a research tool that allows us to overexpress specific BSHs in the gut microbiota to manipulate the BBAA pool. The innovation of this proposal is the use of engineered native bacteria, which allow the stable overexpression of single BSH enzymes in the lumen without disrupting the native microbiota. Preliminary data show that an engineered native bacteria expressing BSH is protective against colitis. The overall goal of this study is to determine how BSH has this effect. The candidate will colonize mice with BSH-expressing engineered native bacteria to test the central hypothesis that BSH protects against colitis through the production of specific BBAAs. In the next three years, the candidate will pursue this hypothesis with two specific aims. The first aim will determine if BBAA production is necessary for BSH to protect against colitis. The candidate will administer engineered native bacteria that produce different BSHs to mice in the dextran sodium sulfate colitis model and determine whether only BSHs that produce BBAAs reduce colitis severity. The second aim will determine if BBAAs are sufficient to recapitulate the effects of BSH. The candidate will administer synthesized BBAAs to mice in the dextran sodium sulfate colitis model and determine if BBAAs alone are protective against colitis. The expected outcome of this study is a mechanistic understanding of how BSH activity ameliorates colitis, and clarity as to whether the production of certain BBAAs mediates this effect. These findings will have a positive translational impact, since characterizing microbial metabolites that ameliorate colitis could provide new therapeutic targets for the development of IBD treatments. The candidate is an outstanding scientist with a clear goal of establishing herself as an independent researcher specializing in the host-microbiome interface in inflammatory disease. Her training objectives include: designing experiments with engineered native bacteria, conducting microbiome and metabolomics studies, gaining expertise in animal models of inflammatory bowel disease, acquiring the skills necessary for independent research, and expanding her professional network. To achieve these objectives, she has developed a comprehensive plan that integrates hands-on bench research, targeted coursework, seminars, participation in national meetings, and other career development activities. This plan will be carried out under the guidance of a mentorship committee led by Drs. Amir Zarrinpar and Pieter Dorrestein.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $43,889 )
2026	2026	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	1	3/23/2026	NEW	$0
2026	2026	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	3/23/2026	NEW	$43,313
2026	2026	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	002	1	7/8/2026	NEW	$576
														Subtotal = $43,889

Grand Total All Awards = $43,889

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The Impact of Bile Salt Hydrolase on Intestinal T Cells in Colitis

Award Number: F31DK145221

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 03/26/2026

PERIOD OF PERFORMANCE END DATE: 03/25/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer